The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The fixed-dose combination product Budesonide/Glycopyrronium/Formoterol Fumarate Inhalation
Aerosol, BGF pMDI and dual combination product Glycopyrronium/Formoterol Fumarate Inhalation
Aerosol , GFF pMDI are developed for maintenance treatment for patients with COPD.
There are still some unmet medical needs and evidence gaps in COPD therapy, such as could BGF
Inhalation Aerosphere reverse the disease progression such like airway-remodelling? Could BGF
Inhalation Aerosphere reduce inflammation in small airways? Before differences proven between
medication groups, pilot study is needed.
This 52 weeks, Single-center, prospective, interventional pilot study could help discovering
intervention effect of BGF and GFF on small airways through OCT measurement, which would show
outcome of AEROSPHERE™ Delivery Technology on COPD patients.